Open AccessPooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma
Author(s) -
Jiajia Sun,
Chi Zhang,
Jun Zhou,
Huilin Yang
Publication year - 2015
Publication title -
asian pacific journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 75
eISSN - 2476-762X
pISSN - 1513-7368
DOI - 10.7314/apjcp.2015.16.8.3163
Subject(s) - pomalidomide , multiple myeloma , medicine , tolerability , oncology , refractory (planetary science) , dexamethasone , lenalidomide , clinical trial , bortezomib , adverse effect , pharmacology , biology , astrobiology
Patients with refractory or relapsed multiple myeloma are considered to have a very poor prognosis, and new regimens are needed to improve this setting. Pomalidomide is a new immunomodulatory drug with high in vitro potency. Immunomodulatory drugs are hypothesized to act through multiple mechanisms. Here we performed a systemic analysis to evaluate pomalidomide-based chemotherapy (pomalidomide in combination with low-dose dexamethasone) as salvage treatment for patients with refractory and relapsed multiple myeloma.